NCT01754558

Brief Summary

During the last decade numerous new procedures have been presented regarding surgical treatment of urinary stress incontinence (1,2). Development of the midurethral tape procedure (TVT) changed the surgical procedure dramatically both regarding the extent of the surgical procedure and also decreased the morbidity remarkably. The success rate of the TVT procedure has been proven to be high (1,2 ). However, the development of the TOT/TVT-O procedures disclosed a new fixation point and further decreased the risk of bladder injury (1,2). Since the introduction of trans-obturator slings several mini-slings have been introduced in order to reduce the need of perforation of the skin and muscles (3,4,5). Although some systems seem promising (5) others have disclosed a long learning curve, pain problems following the procedure and lower success rates, compared to the traditional sling procedures. None of these mini-slings have been adjustable. Recently the Ajust system for treatment of stress urinary incontinence was introduced. The system is a single incision sling procedure and consists of an adjustable Polypropylene mesh sling with self fixation anchors (6). In a feasibility study (6), the 6 months objective cure rate was 82%, but there is a lack of information regarding adverse events and durability of treatment success. Our preliminary experiences suggest, that the procedure has a rapid learning curve, low pain scores postoperatively and a 94% cure rate at 3 months follow-up (personal observation). Recently, several abstracts have indicated that the cure rate obtained by Ajust is comparable to TVT or TVT-O (10-12). The purpose of the present study is (primary outcome): To test the hypothesis that the Ajust and TVT, TVT-O and TOT, respectively are equal regarding subjective cure rate (cure is defined as subjectively not incontinent at all), i.e. the study is designed as a non-inferiority study. The study is performed as a randomised controlled trial without blinding. The study is powered to detect a 9% difference between the two groups. The subjective cure rate is based on ICIQ measurement Secondary outcome:

  • To test the hypothesis that Ajust is associated with a significantly lower postoperative pain perception.
  • To test the hypothesis that antibiotic treatment is not necessary

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 28, 2011

Completed
4 months until next milestone

Study Start

First participant enrolled

May 1, 2012

Completed
8 months until next milestone

First Posted

Study publicly available on registry

December 21, 2012

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2014

Completed
Last Updated

May 2, 2014

Status Verified

May 1, 2014

Enrollment Period

1.9 years

First QC Date

December 28, 2011

Last Update Submit

May 1, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • A change in number of cured patients

    Primary endpoint: A change in number of cured patients. The number of patients cured is anticipated to be equal in each group. A cured patients is defined as having no subjective symptoms (i.e. no scores on the ICIQ-UI SF and ICIQ-OAB) and no objective detectable urinary leakage during coughing (300cc in the bladder and no leakage during coughing.

    Up to 1 year

Secondary Outcomes (1)

  • Pain-perception following surgery

    Evaluated the first week following surgery, and at three and 12 months follow-up

Other Outcomes (1)

  • number of urinary tract infections and infections related to the vaginal closure during the first postoperative months.

    Evaluated during the first week of follow-up and at 3 months follow-up

Study Arms (2)

Ajust sling

EXPERIMENTAL

The sling a a new device for stress urinary incontinence. The sling is ajustable and is not penetrating the skin, i.e. is only attached to the obturator membrane

Procedure: Ajust systemProcedure: TVT/TVT-O

TVT/TVT-O, polypropylne slings

EXPERIMENTAL

TVT/TVT-O system. These two systems is wellknown and used for treatment of stress urinary incontinence. The sling penetrate the skin in order to secure adjustment.

Procedure: Ajust systemProcedure: TVT/TVT-O

Interventions

Ajust systemPROCEDURE

The use of Ajust system for stress incontinence

Ajust slingTVT/TVT-O, polypropylne slings
TVT/TVT-OPROCEDURE

sling surgery

Ajust slingTVT/TVT-O, polypropylne slings

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • \- 1. A medical history of stress urinary incontinence, i.e. leakage during coughing, sneezing or leakage during physical exertion. OR 2. A medical history of mixed urinary stress incontinence defined as complaint of involuntary leakage associated with urgency and stress incontinence. Stress incontinence has to the dominating symptom defined as more episodes of leakage due to coughing or physical exertion than with urgency.
  • \. A provocative stress test up to ten coughs at a standardized bladder volume (300 ml) confirming urinary leakage from the urethra while the patient is asked to cough or perform a Valsalva manoeuvre standing or lying (7). Furthermore, the patient has to present hypermobility of the urethra/bladder neck defined as significant downward rotation when coughing or during Valsalva.?

You may not qualify if:

  • Previous anti-incontinence surgery.
  • Residual urine volume \>100 ml
  • Bladder capacity \<200ml according to diary.
  • Planned or current pregnancy
  • Repeated urinary tract infections (\>4 cystitis last year )
  • Current anticoagulation therapy that can´t be interrupted in due time prior to surgery
  • Known abnormal coagulation
  • Allergy to local anaesthetics
  • Co-existing pelvic pathology, such as ovarian mass etc
  • Vaginal POPQ anterior prolapse grade \>=2
  • A medical history of predominantly urge urinary incontinence.
  • Patients unable to understand the protocol and a follow up
  • Patients younger than 18 and above or equal to 60 years.
  • Known or suspected neurological condition
  • Patients who have not paused acethylsalicylic acid (ASA) medication 7 days prior to surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Martin Rudnicki

Roskilde, Roskilde, 4000, Denmark

Location

Related Publications (2)

  • Temtanakitpaisan T, Buppasiri P, Lumbiganon P, Laopaiboon M, Rattanakanokchai S. Prophylactic antibiotics for preventing infection after continence surgery in women with stress urinary incontinence. Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD012457. doi: 10.1002/14651858.CD012457.pub2.

  • Rudnicki M, von Bothmer-Ostling K, Holstad A, Magnusson C, Majida M, Merkel C, Prien J, Jakobsson U, Teleman P. Adjustable mini-sling compared with conventional mid-urethral slings in women with urinary incontinence. A randomized controlled trial. Acta Obstet Gynecol Scand. 2017 Nov;96(11):1347-1356. doi: 10.1111/aogs.13205. Epub 2017 Sep 15.

MeSH Terms

Conditions

Urinary Incontinence, Stress

Condition Hierarchy (Ancestors)

Urinary IncontinenceUrination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ass. Professor

Study Record Dates

First Submitted

December 28, 2011

First Posted

December 21, 2012

Study Start

May 1, 2012

Primary Completion

April 1, 2014

Study Completion

April 1, 2014

Last Updated

May 2, 2014

Record last verified: 2014-05

Locations